Jain N, Lamb AV, O’Brien S et al (2016) Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood 127(15):1863–1869. https://doi.org/10.1182/blood-2015-08-661702

Article  CAS  Google Scholar 

Borowitz MJ, Chan JKC, Bene MC, Arber DA (2017) T-lymphoblastic leukemia/lymphoma. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO Classification of Tumors of Haematopoetic and Lymphoid Tissues, 4th edn. International agency for research on cancer (IARC), Lyon, pp 209–213

Google Scholar 

Morita K, Jain N, Kantarjian H et al (2021) Outcome of T-cell acute lymphoblastic leukemia/lymphoma: focus on near-ETP phenotype and differential impact of nelarabine. Am J Hematol. 96(5):589–598. https://doi.org/10.1002/ajh.26144

Article  CAS  Google Scholar 

ALL response criteria. In: NCCN guidelines for patients. 2021. p 33. https://www.nccn.org/patients/guidelines/content/PDF/all-patient.pdf

Chopra A, Bakhshi S, Pramanik SK et al (2014) Immunophenotypic analysis of T-acute lymphoblastic leukemia. A CD5-based ETP-ALL perspective of non-ETP T-ALL. Eur J Haematol. 92(3):211–218. https://doi.org/10.1111/ejh.12238

Article  CAS  Google Scholar 

Genescà E, Morgades M, Montesinos P et al (2020) Unique clinico-biological, genetic and prognostic features of adult early T-cell precursor acute lymphoblastic leukemia. Haematologica 105(6):294–297. https://doi.org/10.3324/haematol.2019.225078

Article  Google Scholar 

Iqbal N, Sharma A, Raina V et al (2014) Poor response to standard chemotherapy in early T-precursor (ETP)-ALL: a subtype of T-ALL associated with unfavourable outcome: a brief report. Indian J. Hematol. Blood Transfus. 30(4):215–218. https://doi.org/10.1007/s12288-013-0329-1

Article  Google Scholar 

Zhang Y, Qian JJ, Zhou YL et al (2020) Comparison of early T-cell precursor and non-ETP subtypes among 122 Chinese adults with acute lymphoblastic leukemia. Front Oncol 10:1423. https://doi.org/10.3389/fonc.2020.01423

Article  Google Scholar 

Coustan-Smith E, Mullighan CG, Onciu M et al (2009) Early T-cell precursor leukemia: a subtype of very high-risk acute lymphoblastic leukemia. Lancet Oncol 10(2):147–156. https://doi.org/10.1016/S1470-2045(08)70314-0

Article  CAS  Google Scholar 

Tembhare PR, Sriram H, Khanka T et al (2020) Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy. J Immunother. Cancer 8(1):e000630. https://doi.org/10.1136/jitc-2020-000630

Article  Google Scholar 

Fuhrmann S, Schabath R, Möricke A et al (2018) Expression of CD56 defines a distinct subgroup in childhood T-ALL with inferior outcome. Results of the ALL-BFM 2000 trial. Br J Haematol. 183(1):96–103. https://doi.org/10.1111/bjh.15503

Article  CAS  Google Scholar 

Patrick K, Wade R, Goulden N et al (2014) Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol. 166(3):421–424. https://doi.org/10.1111/bjh.12882

Article  CAS  Google Scholar 

Haydu JE, Ferrando AA (2013) Early T-cell precursor acute lymphoblastic leukemia. Curr. Opin. Hematol. 20(4):369–373. https://doi.org/10.1097/MOH.0b013e3283623c61

Article  CAS  Google Scholar 

McEwan A, Pitiyarachchi O, Viiala N (2020) Relapsed/refractory ETP-ALL successfully treated with venetoclax and nelarabine as a bridge to allogeneic stem cell transplant. Hemasphere 4(3):379. https://doi.org/10.1097/HS9.0000000000000379

Article  Google Scholar 

Angelova E, Audette C, Kovtun Y et al (2019) CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia. Haematologica 104(4):749–755. https://doi.org/10.3324/haematol.2018.205252

Article  CAS  Google Scholar 

Chen Y, Zhang L, Huang J et al (2017) Dasatinib and chemotherapy in a patient with early T-cell precursor acute lymphoblastic leukemia and NUP214-ABL1 fusion: a case report. Exp Ther Med 14(5):3979–3984. https://doi.org/10.3892/etm.2017.5046

Article  CAS  Google Scholar 

Maude SL, Dolai S, Delgado-Martin C et al (2015) Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood 125(11):1759–1767. https://doi.org/10.1182/blood-2014-06-580480

Article  CAS  Google Scholar 

Mamonkin M, Rouce RH, Tashiro H, Brenner MK (2015) A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood 126(8):983–992. https://doi.org/10.1182/blood-2015-02-629527

Article  CAS  Google Scholar 

Khogeer H, Rahman H, Jain N et al (2019) Early T precursor acute lymphoblastic leukemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy. Br J Haematol. 186(4):538–548. https://doi.org/10.1111/bjh.15960

Article  CAS  Google Scholar 

Frismantas V, Dobay MP, Rinaldi A et al (2017) Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood 129(11):e26–e37. https://doi.org/10.1182/blood-2016-09-738070

Article  CAS  Google Scholar